Is ARQT a buy according to AI stock analysis?

ARQT scores 66 out of 100 on the Pineify AI analysis framework, reflecting a commercial-stage biotech that has turned its ZORYVE franchise into a cash-generative business, crossed into operating breakeven on a TTM basis, and guided to sustained profitability, balanced against single-product concentration, competitive and payer pressure, and a valuation that already prices in continued label expansion. ARQT may suit investors comfortable with biotech binary event risk who believe ZORYVE label expansion and market share gains will continue, but it carries higher uncertainty than an established profitable company.

What is the ARQT AI stock forecast?

The ARQT AI stock forecast considers three scenarios over the next 12-24 months based on ZORYVE commercial execution, label expansion, and competitive dynamics. The bull case ($36 to $44) assumes strong Q2 2026 results, on-time infant atopic dermatitis approval, and positive pipeline readouts. The base case ($27 to $36) assumes revenue lands within the $480 to $495 million FY2026 guidance and the stock recovers toward the consensus target near $34.63. The bear case ($15 to $22) assumes disappointing quarters, competitive or FDA setbacks, and multiple compression. These are scenario ranges, not price predictions.

What technical levels matter for ARQT?

Key technical levels for ARQT include resistance at the 52-week high of $31.77 and immediate resistance near $28.00 to $28.50. On the downside, support sits at the 50-day moving average near $25.45, the 200-day moving average near $25.33, the $24.00 round number, and major support near $22.00. The invalidation level for the current uptrend is a daily close below $24.00. RSI near 43 signals a neutral, post-correction reading, and short interest near 10.8% of shares outstanding adds event risk.

Can AI predict ARQT stock price?

No, AI cannot reliably predict stock prices. The ARQT AI stock analysis uses publicly available data, fundamental metrics, and scenario analysis to frame possible outcomes, not to forecast exact prices. Stock prices depend on countless variables including FDA decisions, clinical trial results, competitive launches, payer coverage changes, and market sentiment. Any price targets on this page are scenario-based ranges for informational use, not predictions.

How should I use this ARQT AI trading strategy?

The ARQT AI trading strategy provides educational frameworks for trend-following and mean-reversion approaches, not personalized investment advice. Trend-following entries may watch for a hold of the 50/200-day moving average cluster and a reclaim of the $28.00 to $28.50 zone, while mean-reversion setups watch for a bounce off support ahead of the August 5, 2026 earnings date. Position sizing should account for ARQT above-average volatility and binary event risk around earnings and FDA dates.

What is ZORYVE and why does it matter for ARQT?

ZORYVE (roflumilast) is a topical PDE4 inhibitor approved for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis, sold as a cream and a foam. It is Arcutis main marketed product and the primary driver of company revenue. ZORYVE offers a steroid-free treatment option for inflammatory skin conditions. Label expansion into infants with atopic dermatitis (PDUFA February 23, 2027) and new Phase 2 indications such as vitiligo represent the main upside catalysts for ARQT stock.

What are the main risks for ARQT stock?

The main risks for ARQT include single-product franchise dependence on ZORYVE, regulatory risk around label expansion, competitive pressure from Novartis, Leo Pharma, Bausch Health, and Pfizer, payer coverage and reimbursement limitations including gross-to-net deductions, short interest near 10.8% of shares outstanding, and biotech sector volatility driven by sentiment and binary event outcomes around earnings and FDA decisions.

When does Arcutis report Q2 2026 results?

Arcutis is scheduled to report Q2 2026 financial results and host a conference call on August 5, 2026 after market close. Consensus expectations as of the August 4, 2026 data cutoff were for roughly $118.85 million in revenue and adjusted EPS near $0.05. This snapshot does not include Q2 2026 results, so the earnings report is a near-term binary catalyst for the stock.

Arcutis Biotherapeutics, Inc. research snapshot

ARQT AI Stock Analysis

ARQT AI stock analysis reads Arcutis Biotherapeutics as a commercial-stage dermatology company that has turned its ZORYVE (roflumilast) franchise into a growing, cash-generative business. At the August 4, 2026 data cutoff, ARQT traded near $25.68 with a verified market capitalization near $3.21 billion, down about 19% from the 52-week high of $31.77. The company reported FY2025 net product revenue of $376.07 million, up 91.3% year over year, generated roughly $27 million of positive trailing twelve month operating cash flow, and guided to $480 to $495 million of net product revenue for FY2026. Q2 2026 results are scheduled for August 5, 2026 and were not included in this snapshot. This page uses scenario ranges and source checks, not a certain stock price prediction, and is for informational use only.

Current price

$25.68

Market cap

$3.21 billion

AI score

66 / 100

Rating

Commercial-stage dermatology biotech turning operating breakeven, with ZORYVE growth and near-term profitability in sight

Trend status

Pulled back roughly 19% from the 52-week high to test the 50/200-day moving average cluster after a strong multi-quarter advance

Data cutoff (updated monthly)

August 4, 2026

Informational use only. This page is not investment advice.

Research quality check

information Richness: B-level information richness. Arcutis has quarterly filings, multiple FDA label decisions, analyst coverage (8 analysts), proxy filings, and a track record of commercial quarters. Data is more limited for long-term margin structure, competitive response from established dermatology franchises, and the revenue contribution of pipeline indications still in Phase 2.
bias Check: The main AI bias risk is extrapolating recent ZORYVE growth as a smooth linear trend while underestimating competitive and payer pressure in a crowded topical dermatology market. The reverse check asks whether market access, primary care and pediatric expansion, and physician adoption can sustain the current growth rate as the base gets larger.
ai Confidence: High for current price, share count, market cap math, FY2025 and Q1 2026 financials, guidance, and analyst targets. Medium for future revenue trajectories, label expansion timing, margin progression, and competitive dynamics that depend on regulatory events and commercial execution.
investment Certainty: Medium. Arcutis has proven product-market fit, crossed into operating breakeven, and carries a net cash balance, but the stock still trades at a premium sales multiple that embeds continued label expansion, market share gains, and durable profitability. The gap between data confidence and investment certainty is narrower than for early-stage biotechs but wider than for established profitable pharmaceutical companies.

Quick verdict table

Dimension	Conclusion	Confidence
Business quality	Arcutis sells patented topical PDE4 inhibitor therapies (ZORYVE) for inflammatory skin diseases through a dermatology sales force, now expanding into primary care and pediatrics. ZORYVE holds the leading prescribed position among branded topical treatments across its approved indications.	Medium
Moat	Moat comes from ZORYVE patents, FDA-approved label exclusivity, formulation know-how, clinical evidence, and guideline support such as the strong recommendation in the AAD pediatric atopic dermatitis guidelines. Rivals can develop competing topicals, and branded market access still depends on formulary placement.	Low-medium
Management	CEO Frank Watanabe has steered Arcutis from development to a commercial stage that is now generating positive operating cash flow. Recent execution includes completing the dermatology sales force expansion, building a primary care and pediatrics team, submitting an infant atopic dermatitis sNDA, and advancing ARQ-234 into Phase 1. Capital allocation and the profitability ramp are the open questions.	Medium
Financial trend	Revenue grew from $196.54M in FY2024 to $376.07M in FY2025 (+91.3%), and TTM revenue reached $415.62M. Gross margins are stable near 90%. Operating income turned positive on a TTM basis (+$3.21M), with TTM operating cash flow near +$27M and TTM free cash flow near +$27M. Net loss narrowed to -$16.14M in FY2025 and to -$2.38M on a TTM basis.	Medium-high
Valuation	At $25.68 and $3.21B market cap, ARQT trades at roughly 7.9x TTM revenue, 6.4x FY2026E consensus revenue of about $500M, and an 83x forward P/E on FY2026E EPS of $0.18. The valuation assumes continued label expansion and sustained profitability, with upside to FY2027E EPS of $1.13 if execution holds.	Medium
Technical trend	ARQT is up about 82% over the last 52 weeks but has corrected roughly 19% from the 52-week high of $31.77, now testing its 50-day moving average ($25.45) and 200-day moving average ($25.33), which are converging near the current price. RSI of 43 signals a neutral, post-correction reading.	Medium
Risk level	Elevated. Regulatory dependence (FDA label expansion, PDUFA dates), competitive pressure in topical dermatology, payer access and formulary placement, short interest near 10.8% of shares outstanding, single-product franchise risk, and volatile biotech sentiment around earnings and FDA news.	Medium
AI confidence	Medium. Price, financials, guidance, cash position, and analyst targets are well-sourced. Competitive positioning, margin trajectory, and label expansion outcomes depend on execution and regulatory events that require ongoing monitoring.	Medium
Investment certainty	Medium. Arcutis is now a real, cash-generative commercial business approaching GAAP profitability, but the stock price still embeds optimism about continued ZORYVE expansion and pipeline progress. Data confidence is high; investment certainty is moderated by valuation and single-product concentration.	Medium

ARQT AI stock forecast

ARQT AI Stock Forecast Scenarios

Three ARQT scenarios explore how ZORYVE label expansion, Q2 2026 results, pipeline readouts, competitive dynamics, and execution toward profitability could affect the stock over the next 12-24 months. These are not predictions, only probability-weighted ranges.

Bull case

$36 - $44

Q2 2026 results beat consensus and FY2026 revenue lands at the top of guidance or above. The infant atopic dermatitis sNDA (PDUFA February 23, 2027) is approved on time, expanding the addressable population. ZORYVE Phase 2 readouts in vitiligo (Q4 2026) and hidradenitis suppurativa (decision Q1 2027) are positive. Sustained profitability and primary care/pediatric expansion drive a re-rating toward and beyond analyst high targets of $36.

Base case

$27 - $36

Q2 2026 results are in line and FY2026 revenue lands within the $480 to $495 million guidance range. ZORYVE continues to gain share at a moderate pace with gradually improving payer access. Operating profitability holds, ARQ-234 Phase 1 advances, and the stock recovers toward the consensus target of about $34.63 on a 6-7x forward revenue multiple.

Bear case

$15 - $22

Q2 2026 or Q3 2026 results disappoint on slower prescription growth, payer pressure, or heavier gross-to-net deductions. A competitive launch or FDA setback delays a key label expansion. Phase 2 pipeline readouts are negative or delayed, and profitability slips. The premium sales multiple compresses toward lower-growth biotech levels, and the stock falls below the moving average cluster toward the low $20s.

ARQT AI technical analysis

ARQT AI Technical Analysis

Technical levels as of the August 3, 2026 close. ARQT completed a strong multi-quarter advance from the 52-week low of $13.70 to a high of $31.77 and has since corrected to near $25.68, where the 50-day and 200-day moving averages have converged. Levels are based on current chart data and may shift with new data.

Level	Value	Why it matters
Resistance (52-week high)	$31.77	Cycle peak set before the current pullback. A clean close above would signal trend resumption and open the path toward analyst targets of $33 to $36.
Immediate resistance	$28.00 - $28.50	Early-July trading zone before the recent decline. Reclaiming this area would improve short-term momentum ahead of the August 5, 2026 earnings report.
Support (50-day MA)	$25.45	Short-term trend level now being tested. Holding above this moving average keeps the near-term structure intact.
Support (200-day MA)	$25.33	Long-term trend line converging with the 50-day MA near the current price. This cluster is the key battleground for the trend.
Key support (round number)	$24.00	Psychological level below the moving average cluster. A close below it with volume would signal that momentum is fading.
Major support	$22.00	Prior structural zone from the spring 2026 advance. This level becomes relevant only in a meaningful trend reversal.
Momentum (RSI 14-day)	43.3	Neutral reading after the correction, no longer overbought. There is room for recovery, but no oversold bounce signal yet.
Volume and positioning	1.26M avg, ~10.8% short interest	Twenty-day average volume near 1.26M shares. Short interest of about 10.8% of shares outstanding adds squeeze potential on positive catalysts but also gap-down risk on disappointments.
Volatility (beta)	1.48	Above-average price volatility for the market. Expect wide swings around the August 5, 2026 earnings date and FDA decision points.
Invalidation level	Close below $24.00	A daily close below the 50/200-day MA cluster and the $24 round number would signal trend damage. A break below the 52-week low of $13.70 would invalidate the current uptrend and suggest a fundamental reassessment.

ARQT AI trading strategy

ARQT AI Trading Strategy Framework

These frameworks are for informational and educational use. They are not personalized investment advice. ARQT is a commercial-stage biotech with binary event risk around Q2 2026 earnings (August 5, 2026), FDA decisions, payer coverage changes, pipeline readouts, and competitive dynamics. Position sizing should account for above-average volatility.

Trend-following setup

Watch whether price holds the 50/200-day moving average cluster near $25.33 to $25.45. If support holds and price reclaims the $28.00 to $28.50 zone, the correction may be a dip within a larger uptrend. Enter on confirmed momentum and set initial targets near the 52-week high ($31.77) and then analyst targets ($33 to $36).

Stop below the $24.00 round-number support. If the stock closes below the 200-day MA with volume, the trend has likely turned. Position size at 2-3% of portfolio given biotech volatility.

Mean-reversion setup

After a roughly 19% pullback from the high, mean-reversion entries can target a bounce off the moving average cluster if Q2 2026 results confirm fundamentals. Key catalyst zones are the August 5, 2026 earnings date, FDA decision dates, and Phase 2 pipeline readouts in late 2026.

Define the catalyst date and exit if the thesis does not materialize within the expected timeframe. Biotech gaps can be large; use defined-risk option structures if available.

Risk controls

ARQT is a single-product franchise with regulatory and commercial binary risk. No single position should expose more than 5% of portfolio. Consider reducing exposure ahead of the August 5 earnings date and FDA decision points that carry wide expected moves.

Set a maximum loss threshold before entering. If the stock gaps down more than 20% on negative news, reassess the fundamental thesis before adding to the position. Do not average down into a broken thesis.

Investment research summary

Four-master Research Compression

Business essence

Arcutis develops and commercializes topical PDE4 inhibitor therapies for inflammatory skin diseases. Its lead product ZORYVE (roflumilast) is approved in cream and foam forms for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis, and management describes it as the leading prescribed branded topical across those indications. The company is now extending distribution beyond dermatology into primary care and pediatrics.

Moat assessment

ZORYVE patent protection, FDA label exclusivity, formulation IP, clinical evidence, and guideline support provide competitive insulation. However, dermatology is crowded with established brands from Novartis, Leo Pharma, Bausch Health, and Pfizer, and switching costs for physicians who can prescribe competing topicals are low. The moat is narrow and depends on continued innovation, label expansion, and market access execution.

Munger risk inversion

The thesis fails if: (1) ZORYVE growth decelerates sharply as the revenue base grows, (2) payer coverage and reimbursement, or higher gross-to-net deductions, narrow the addressable market, (3) a competitor launches a superior or cheaper topical that captures share, (4) Q2 2026 or later results miss on earnings due to seasonal or access factors, (5) pipeline readouts in vitiligo or hidradenitis suppurativa fail and remove the next leg of growth, or (6) the company needs dilutive financing before achieving sustained GAAP profitability.

Management evaluation

CEO Frank Watanabe has led Arcutis from development through multiple FDA approvals, commercial launch, and now the transition to operating profitability. Recent moves include completing the dermatology sales force expansion, hiring a head of Primary Care Franchise, building a primary care and pediatrics organization, and submitting an sNDA to expand ZORYVE cream to infants with atopic dermatitis. Key questions include how the larger commercial base holds up under competition and how capital is allocated between pipeline investment and the profitability ramp.

Industry trend

Dermatology is a large and growing market driven by an aging population, rising skin disease awareness, and demand for steroid-sparing treatments. The shift toward targeted topicals (PDE4, JAK, and AhR agonists) creates room for newer agents, and guideline support such as the AAD pediatric atopic dermatitis recommendation is a tailwind. Payer scrutiny of branded specialty topicals is increasing, and competitive pressure from established franchises remains intense.

Valuation and margin of safety

At $25.68 and $3.21B market cap, ARQT trades at roughly 7.9x TTM revenue, about 6.4x FY2026E revenue of $500 million, and an 83x forward P/E on FY2026E EPS of $0.18. Analyst price targets range from $33 to $36, with a consensus near $34.63. The valuation already embeds continued label expansion and sustained profitability, so the margin of safety is limited if growth decelerates or pipeline readouts disappoint.

Source-backed data

ARQT Data Table

Every metric below includes a source and last verification date.

Metric	Value	Source	Last verified
Current price	$25.68	StockAnalysis, Google Finance	2026-08-03
Market capitalization	$3.21 billion	StockAnalysis, Google Finance	2026-08-03
Shares outstanding	125.08 million	StockAnalysis, Google Finance	2026-08-03
Revenue (FY2025)	$376.07 million	StockAnalysis	2026-08-03
Revenue (TTM)	$415.62 million	StockAnalysis	2026-08-03
Net income (FY2025)	-$16.14 million	StockAnalysis	2026-08-03
Net income (TTM)	-$2.38 million	StockAnalysis	2026-08-03
EPS (TTM)	-$0.02	StockAnalysis, Google Finance	2026-08-03
Q1 2026 net product revenue	$105.4 million (up 65% YoY)	Arcutis Q1 2026 press release	2026-08-04
Q1 2026 net loss	-$11.3 million (-$0.09 per share)	Arcutis Q1 2026 press release	2026-08-04
FY2026 revenue guidance	$480M - $495M	Arcutis Q1 2026 press release	2026-08-04
Operating cash flow (TTM)	+$26.99 million	StockAnalysis	2026-08-03
Free cash flow (TTM)	+$26.92 million	StockAnalysis	2026-08-03
Cash and investments	$224.3 million (March 31, 2026)	Arcutis Q1 2026 press release	2026-08-04
Total debt	$114.67 million	StockAnalysis	2026-08-03
52-week high	$31.77	StockAnalysis, Google Finance	2026-08-03
52-week low	$13.70	StockAnalysis, Google Finance	2026-08-03
Employees	354	StockAnalysis, Google Finance	2026-08-03
Analyst consensus	Buy (8 analysts), average target $34.63, range $33 - $36	StockAnalysis (S&P Global, TipRanks)	2026-08-03
FY2026E revenue	$500.09 million (+33.0%)	StockAnalysis (S&P Global)	2026-08-03
FY2026E EPS (adjusted)	$0.18	StockAnalysis (S&P Global)	2026-08-03

Frequently Asked Questions

View GILD AI Stock Analysis View BIIB AI Stock Analysis View AMGN AI Stock Analysis View BMY AI Stock Analysis Pineify AI Stock Picker AI Stock Screener

This ARQT AI stock analysis page is an informational tool only and does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security. All analysis is based on publicly available data as of the August 4, 2026 data cutoff and uses scenario frameworks that may prove incorrect. Forecasts are scenarios based on available data and can be wrong. Past performance is not indicative of future results. Investing in biotech stocks carries risks including potential total loss of capital. Always conduct your own research and consult a qualified financial advisor before making investment decisions.